Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on April 28, 2025
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti-amyloid gene therapy for Alzheimer’s …
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire
·
April 28, 2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils …
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
GlobeNewswire
·
April 28, 2025
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today …
Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
SOMERVILLE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced seven presentations of new preclinical data at the upcoming American …
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
GlobeNewswire
·
April 28, 2025
DUBLIN and BRIDGEWATER, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President …
Turtle Beach Corporation to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025
GlobeNewswire
·
April 28, 2025
WHITE PLAINS, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Turtle Beach Corporation (Nasdaq: TBCH) a leading gaming headset and accessories brand, today announced it will report financial results for the first quarter 2025 on Thursday, May 8, 2025, after the …
Two Senior Executives Join the Diginex Team to Drive Sustainable Finance Initiatives and strategic M&A
GlobeNewswire
·
April 28, 2025
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex”) (NASDAQ: DGNX), a leading impact technology company focused on solving pressing environmental, social, and governance (ESG) challenges, is thrilled to announce the appointment of two …
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
GlobeNewswire
·
April 28, 2025
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, …
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
GlobeNewswire
·
April 28, 2025
Lille (France), Cambridge (Massachusetts, Etats-Unis), Zurich (Suisse), 28 avril 2025 - GENFIT (Nasdaq et Euronext : GNFT), société biopharmaceutique spécialisée dans l'amélioration de la vie des patients atteints de maladies rares du foie pouvant engager …
Countdown to CoinW’s TOKEN2049 side event: Navigating Dubai’s policy landscape and crypto’s future
GlobeNewswire
·
April 28, 2025
DUBAI, United Arab Emirates, April 28, 2025 (GLOBE NEWSWIRE) -- As TOKEN2049 Dubai draws near, the global cryptocurrency community is increasingly focused on the city’s growing influence in shaping the future of digital assets. As a platinum sponsor of …
Rigetti Computing to Report First Quarter 2025 Financial Results and Host Conference Call on May 12, 2025
GlobeNewswire
·
April 28, 2025
BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. ("Rigetti" or the "Company") (Nasdaq: RGTI), a pioneer in hybrid quantum-classical computing, announced today that it will release first quarter 2025 results on May 12, 2025 after …
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will …
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
GlobeNewswire
·
April 28, 2025
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations …
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
·
April 28, 2025
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS …
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
GlobeNewswire
·
April 28, 2025
SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel …
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation …
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
GlobeNewswire
·
April 28, 2025
WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights ( …
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced new preclinical data in collaboration with Moderna on an mRNA …